Merck, Schering-Plough report strong second-quarter sales

Share this article:

Merck and Schering-Plough each reported strong second-quarter sales results today.

Merck's second-quarter highlights included:
*Growth in global sales for asthma and allergic rhinitis treatment Singulair by 15% to $1.1 billion. 
*Global sales growth of antihypertensive medicines Cozaar and Hyzaar of 8% to $847 million.
*Global sales of $358 million for cervical cancer vaccine Gardasil.
*Global sales of $144 million for Januvia, Merck's first-in-class treatment for Type 2 diabetes.

Meanwhile, Schering-Plough's second-quarter sales increased by 13%, to almost $3.2 billion, as the company continues to benefit from a leadership turnaround under Fred Hassan.

Schering-Plough's second-quarter highlights included:
*A global sales increase for arthritis drug Remicade of 28% to $394 million.
*A global sales increase for allergy treatment Nasonex of 22% to $295 million.
*A global sales increase for seasonal allergic rhinitis drug Clarinex to $250 million from $226 million.
*International sales growth for Temodar, a treatment for certain types of brain tumors of 26% to $216 million.
*An increase in sales of Pegintron for hepatitis C of 3% to $234 million, due to higher sales in Latin America and Europe, and tempered by lower sales in the United States and Japan.

Merck and Schering-Plough's quarterly performance was helped by the joint venture between the companies to market cholesterol drugs Vytorin and Zetia. Sales of the drugs rose $1.3 billion in the quarter, up 30% from a year earlier.

Share this article:

Email Newsletters

More in News

Astellas, DOJ settle for $7.3M

Astellas, DOJ settle for $7.3M

Astellas has settled a False Claims case with the Department of Justice over the 2010-2013 marketing of an antifungal medication. Astellas denies the allegations.

Boehringer drug lands US, EU orphan tag

Boehringer drug lands US, EU orphan tag

The experimental Breakthrough Therapy treatment is for acute myeloid leukemia.

Omnio app moves to smartphones

Omnio app moves to smartphones

Physicians Interactive is introducing the third wave of its Omnio app, making the tablet-only tool available for iPhones and Android phones.